Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$71.63-9.58%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
QuarterlyIQ Insights · CORT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition.
President — Sean Maduck: The President of the company resigned, representing the loss of a senior executive, although the transition appears orderly with a consulting agreement in place.
Results of Operations and Financial Condition.
Other Events. On May 19, 2026, Corcept Therapeutics Incorporated (the “Company”) learned that the United States Department of Justice (the “DOJ”) had filed a Notice of Election to Decline Intervention (the “Notice”) in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc. , No. 17-CV-1303 (SRC) (D.N.J.). That action was initiated in February 2017, in the District Court of New Jersey, by a former employee of the Company (t…
The filing is about the approval of an amendment to the company's incentive award plan, which does not involve any changes in management or executive roles.
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
Other Events. On December 31, 2025, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition.
Termination of a Material Definitive Agreement. On October 10, 2025, Corcept Therapeutics Incorporated (the “Company”) delivered to Optime Care, Inc. (“Optime”) a notice of termination of that certain Distribution Services Agreement, dated August 4, 2017, as amended and restated on April 1, 2024, by and between Optime and the Company (the “Agreement”), effective as of January 8, 2026. As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distribut…
Director — Gillian Cannon, Ph.D.: Dr. Gillian Cannon resigned from the Board of Directors.
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
The filing describes the approval of a new equity incentive plan, which is a compensatory arrangement rather than a change in management personnel.
Results of Operations and Financial Condition.
Entry into a Material Definitive Agreement. On April 12, 2024, Corcept Therapeutics Incorporated (“Corcept”) entered into a sublease (the “Sublease”) with Zuora, Inc. for a portion of the premises located at 101 Redwood Shores Parkway, Redwood City, California 94065 (the “Building”). The portion of the premises subject to the Sublease is approximately 50,632 rentable square feet (the “Subleased Premises”). Pursuant to the Sublease, Corcept will also have access to additional square feet of co…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information regarding the Sublease set forth under
Results of Operations and Financial Condition.
Other Events On January 8, 2024, Corcept announced that its Board of Directors approved a program to repurchase up to $200 million of the Company’s common stock (the “Stock Repurchase Program”). The Stock Repurchase Program will be in effect commencing on January 10, 2024. The timing and amount of any repurchases pursuant to the Stock Repurchase Program will be determined based on market conditions, the Company’s stock price and other factors. The Stock Repurchase Program does not require Cor…
Results of Operations and Financial Condition. On January 8, 2024, Corcept Therapeutics Incorporated (“Corcept”) issued a press release announcing its preliminary, unaudited, financial results for the quarter and year ended December 31, 2023. The preliminary, unaudited, financial information presented in the press release is based on Corcept’s current expectations and may be adjusted as a result of, among other things, completion of customary quarter-end and year-end close review procedures a…
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.